• Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • FemmeBreaking barriers and building confidence in investing
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • Investing SchoolGuides and lessons to grow your investing knowledge
    • Portfolio buildersInvesting knowledge for every level, from first steps to advanced portfolio strategies.
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Log in to your Inderes Free account to see all free content on this page.
Create account

Medivir

1.73 SEK

-0.12 %

Less than 1K followers

MVIR

NASDAQ Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Compare
-0.12 %
-8.09 %
+20.84 %
+322.49 %
+354.74 %
-2.70 %
-70.64 %
-73.96 %
-97.05 %

Medivir develops drugs with a focus on cancer diseases where the medical needs are great. The drug candidates are directed towards indication areas where available treatment methods are limited or absent. Medivir focuses on the development of fostrox, a drug candidate that has been designed to selectively treat cancer cells in the liver. The company was founded in 1988 and is headquartered in Huddinge.

Read more
Market cap
935.06M SEK
Turnover
1.35M SEK
Revenue
EBIT %
P/E
Dividend yield-%
Revenue and EBIT-%
EPS and dividend
Financial calendar
20.8.
2026

Interim report Q2'26

5.11.
2026

Interim report Q3'26

All
Webcasts
Press releases
ShowingAll content types

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Press release6/2/2026, 7:20 AM

DNB Carnegie Access: Medivir: Reflections from ASCO 2026 with a focus on HCC

Medivir
Regulatory press release5/21/2026, 7:00 AM

Medivir announces first patient enrolled in FLEX-HCC study

Medivir
Press release5/12/2026, 10:45 AM

DNB Carnegie Access: Medivir – Ett starkare bolag

Medivir

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and deep analyses
Premium tools: model portfolio, screener, insider transactions
Premium columns: Guest column, expert insights
Inderes MCP - Inderes data directly into your AI tools
Create account
Regulatory press release5/7/2026, 2:00 PM

Resolutions at the Annual General Meeting in Medivir on 7 May 2026

Medivir
Press release5/7/2026, 5:09 AM

DNB Carnegie Access: Medivir: Equity story improving on pipeline breadth and financing

Medivir
Press release5/6/2026, 8:43 AM

Redeye: Medivir (Q1 review): Fostrox Study Poised for Start

Medivir
Medivir, Audiocast, Q1'26
Webcast5/5/2026, 12:00 PM

Medivir, Audiocast, Q1'26

Medivir
Regulatory press release5/5/2026, 6:30 AM

MEDIVIR AB – INTERIM REPORT JANUARY – MARCH 2026

Medivir
Press release4/21/2026, 6:30 AM

Medivir participates in the partner and investor conferences Nordic Health Summit in Japan/Korea and BIO KOREA 2026

Medivir
Press release4/17/2026, 6:30 AM

Medivir reschedules report date to May 5

Medivir
Regulatory press release4/8/2026, 6:30 AM

Notice of Annual General Meeting of Medivir AB (publ)

Medivir
Regulatory press release4/1/2026, 1:00 PM

Medivir 2025 Annual Report published

Medivir
Press release3/20/2026, 7:30 AM

Medivir creates Scientific Expert Council with world-leading Osteogenesis Imperfecta specialists

Medivir
Press release3/6/2026, 7:30 AM

Medivir presenting at DNB/Carnegie Healthcare Seminar

Medivir
Press release3/3/2026, 7:30 AM

Medivir recruits Patrik Norgren as new CFO

Medivir
Regulatory press release2/27/2026, 7:30 AM

Number of shares and votes in Medivir AB on 27 February 2026

Medivir
Press release2/26/2026, 10:22 AM

Redeye: Medivir (Q4 review): Directed Issue Unlocked Significant Value

Medivir
Medivir, Audiocast, Q4'25
Webcast2/18/2026, 1:00 PM

Medivir, Audiocast, Q4'25

Medivir
Regulatory press release2/18/2026, 7:30 AM

MEDIVIR AB – YEAR-END REPORT JANUARY – DECEMBER 2025

Medivir
Press release2/12/2026, 7:30 AM

Medivir’s partner Vetbiolix announces initiation of randomized, placebo-controlled study to confirm clinical benefit with VBX-1000 (MIV-701)

Medivir